English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Erectile dysfunction (ED) is a condition that affects approximately 18 million American men. Phosphodiesterase-5 inhibitors (PDE5i’s) have revolutionized the treatment of erectile dysfunction by providing the first highly-effective oral medication. Vardenafil is one of 3 PDE5i’s commercially available for the treatment of ED in the United States. It has demonstrated therapeutic efficacy in the management of uncomplicated ED as well as more refractory cases associated with diabetes and surgery for prostate cancer. The physiology, pharmacokinetics, pharmacodynamics, and primary literature evaluating vardenafil are reviewed.

Vardenafil in Erectile Dysfunction: The Evidence of Its Therapeutic Value